Inventor · disambiguated record
Hung V. Do
Also filed as: DO HUNG · DO HUNG V
32 granted patents·25 pending applications·484 citations·filing 2000–2025
97Inventor score
Top patents by PatentIndex Score
57 records- 0198USRE48608EMethod to predict response to pharmacological chaperone treatment of diseasesAMICUS THERAPEUTICS INC·Filed 2018·Granted Jun 29, 2021·36 cites·44 claims
- 0298US10813921B2Method to predict response to pharmacological chaperone treatment of diseasesAMICUS THERAPEUTICS INC·Filed 2018·Granted Oct 27, 2020·39 cites·18 claims
- 0398US9545397B2Method to predict response to pharmacological chaperone treatment of diseasesAMICUS THERAPEUTICS INC·Filed 2015·Granted Jan 17, 2017·50 cites·1 claims
- 0497US11591583B2Highly potent acid alpha-glucosidase with enhanced carbohydratesAMICUS THERAPEUTICS INC·Filed 2022·Granted Feb 28, 2023·3 cites·16 claims
- 0596US11753632B2Highly potent acid alpha-glucosidase with enhanced carbohydratesAMICUS THERAPEUTICS INC·Filed 2021·Granted Sep 12, 2023·3 cites·19 claims
- 0696US11278601B2Augmented acid alpha-glucosidase for the treatment of Pompe diseaseAMICUS THERAPEUTICS INC·Filed 2020·Granted Mar 22, 2022·5 cites·13 claims
- 0796US8592362B2Method to predict response to pharmacological chaperone treatment of diseasesBENJAMIN ELFRIDA·Filed 2010·Granted Nov 26, 2013·112 cites·4 claims
- 0895US10857212B2Augmented acid alpha-glucosidase for the treatment of Pompe diseaseAMICUS THERAPEUTICS INC·Filed 2018·Granted Dec 8, 2020·7 cites·31 claims
- 0994US10961522B2Highly potent acid alpha-glucosidase with enhanced carbohydratesAMICUS THERAPEUTICS INC·Filed 2019·Granted Mar 30, 2021·9 cites·12 claims
- 1094US10208299B2Highly potent acid alpha-glucosidase with enhanced carbohydratesAMICUS THERAPEUTICS INC·Filed 2015·Granted Feb 19, 2019·12 cites·18 claims
- 1194US9206457B2Utilization of pharmacological chaperones to improve manufacturing and purification of biologicsDO HUNG V·Filed 2010·Granted Dec 8, 2015·50 cites·7 claims
- 1294US9095584B2Method to predict response to pharmacological chaperone treatment of diseasesAMICUS THERAPEUTICS·Filed 2013·Granted Aug 4, 2015·52 cites·10 claims
- 1393US11491243B2Gene therapy constructs and methods of useAMICUS THERAPEUTICS INC·Filed 2020·Granted Nov 8, 2022·4 cites·18 claims
- 1492US10227577B2Method for selection of high M6P recombinant proteinsAMICUS THERAPEUTICS INC·Filed 2017·Granted Mar 12, 2019·11 cites·10 claims
- 1592US9279007B2Signal sequences to improve protein expressions and secretion of recombinant enzymes and other proteinsDO HUNG·Filed 2011·Granted Mar 8, 2016·17 cites·18 claims
- 1691US10874750B2Gene therapy constructs and methods of useAMICUS THERAPEUTICS INC·Filed 2019·Granted Dec 29, 2020·7 cites·19 claims
- 1791US10512676B2Formulations comprising recombinant acid alpha-glucosidaseAMICUS THERAPEUTICS INC·Filed 2017·Granted Dec 24, 2019·14 cites·23 claims
- 1891US9545450B2Methods for coupling targeting peptides onto recombinant lysosomal enzymes for improved treatments of lysosomal storage diseasesDO HUNG·Filed 2012·Granted Jan 17, 2017·21 cites·14 claims
- 1989US10660972B2Methods for coupling targeting peptides onto recombinant lysosomal enzymes for improved treatments of lysosomal storage diseasesAMICUS THERAPEUTICS INC·Filed 2016·Granted May 26, 2020·4 cites·19 claims
- 2089US6517830B1Compositions and methods for the expression of factor VIII polypeptides and uses thereforUNIV EMORY·Filed 2000·Granted Feb 11, 2003·21 cites·12 claims
- 2188US11491211B2Formulations comprising recombinant acid alpha-glucosidaseAMICUS THERAPEUTICS INC·Filed 2019·Granted Nov 8, 2022·3 cites·23 claims
- 2284US11441138B2Method for selection of high M6P recombinant proteinsAMICUS THERAPEUTICS INC·Filed 2019·Granted Sep 13, 2022·1 cites·9 claims
- 2384US2023203465A1Highly Potent Acid Alpha-Glucosidase With Enhanced CarbohydratesAMICUS THERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 2481US2025242057A1Disulfide Bond Stabilized Polypeptide Compositions And Methods Of UseAMICUS THERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 2580US12414985B2Augmented acid alpha-glucosidase for the treatment of Pompe diseaseAMICUS THERAPEUTICS INC·Filed 2022·Granted Sep 16, 2025·0 cites·33 claims
- 2677US12246062B2Recombinant human acid alpha-glucosidaseAMICUS THERAPEUTICS INC·Filed 2018·Granted Mar 11, 2025·1 cites·19 claims
- 2776US8962564B2Variant, recombinant beta-glucocerebrosidase proteins with increased stability and increased retained catalytic activityDO HUNG·Filed 2011·Granted Feb 24, 2015·2 cites·24 claims
- 2876US2025057925A1Recombinant Human Acid Alpha-GlucosidaseAMICUS THERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 2976US2025082621A9Method To Predict Response To Pharmacological Chaperone Treatment Of DiseasesAMICUS THERAPEUTICS INC·Filed 2020·Application pending·0 cites
- 3075US2023079225A1Method For Selection Of High M6P Recombinant ProteinsAMICUS THERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 3174US2025381254A1Augmented Acid Alpha-Glucosidase For The Treatment Of Pompe DiseaseAMICUS THERAPEUTICS INC·Filed 2025·Application pending·0 cites
- 3273US12064485B2Disulfide bond stabilized polypeptide compositions and methods of useAMICUS THERAPEUTICS INC·Filed 2021·Granted Aug 20, 2024·0 cites·20 claims
- 3372US2024066104A1Formulations comprising recombinant acid alpha-glucosidaseAMICUS THERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 3472US2023233711A1Gene therapy constructs and methods of useAMICUS THERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 3570US11097015B2Disulfide bond stabilized polypeptide compositions and methods of useAMICUS THERAPEUTICS INC·Filed 2019·Granted Aug 24, 2021·0 cites·20 claims
- 3666US2025137012A1Compositions and methods of using two-promoter vector for treatment of lysosomal storage disordersM6P THERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 3766US2017189497A1Augmented Acid Alpha-Glucosidase For The Treatment Of Pompe DiseaseAMICUS THERAPEUTICS INC·Filed 2016·Application pending·0 cites
- 3863US9889203B2Chemical crosslinkersAMICUS THERAPEUTICS INC·Filed 2014·Granted Feb 13, 2018·0 cites·8 claims
- 3962US9821038B2Variant, recombinant beta-glucocerebrosidase proteins with increased stability and increased retained catalytic activityAMICUS THERAPEUTICS INC·Filed 2017·Granted Nov 21, 2017·0 cites·20 claims
- 4062US2025041445A1Gene therapy for treatment of mucopolysaccharidosis iiiaUNIV PENNSYLVANIA·Filed 2022·Application pending·0 cites
- 4162US2010119502A1Therapy regimens, dosing regimens and stable medicaments for the treatment of pompe diseaseAMICUS THERAPEUTICS INC·Filed 2009·Application pending·0 cites
- 4261US10814008B2Chemical crosslinkersAMICUS THERAPEUTICS INC·Filed 2018·Granted Oct 27, 2020·0 cites·7 claims
- 4361US2025034533A1Compositions And Methods For Treating Mucopolysaccharidosis IIIAAMICUS THERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 4459US9566316B2Variant, recombinant beta-glucocerebrosidase proteins with increased stability and increased retained catalytic activityAMICUS THERAPEUTICS INC·Filed 2016·Granted Feb 14, 2017·0 cites·20 claims
- 4559US2017003301A1Method to predict response to pharmacological chaperone treatment of diseasesAMICUS THERAPEUTICS·Filed 2016·Application pending·0 cites
- 4657US2022193261A1Compositions useful for treatment of pompe diseaseUNIV PENNSYLVANIA·Filed 2020·Application pending·0 cites
- 4757US2024197839A1Recombinant Human Acid Alpha-Glucosidase and Uses ThereofAMICUS THERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 4856US9254313B2Variant, recombinant beta-glucocerebrosidase proteins with increased stability and increased retained catalytic activityAMICUS THERAPEUTICS INC·Filed 2015·Granted Feb 9, 2016·0 cites·20 claims
- 4956US2011152319A1Method to predict response to pharmacological chaperone treatment of diseasesAMICUS THERAPEUTICS INC·Filed 2010·Application pending·0 cites
- 5055US2023173108A1Compositions useful for treatment of pompe diseaseUNIV PENNSYLVANIA·Filed 2021·Application pending·0 cites
Showing the top 50 of 57 patent records by PatentIndex Score.
Join the waitlist — get patent alerts
Get an alert when Hung V. Do files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →